Literature DB >> 32323202

COVID-19 and dialysis: why we should be worried.

Giuseppe Rombolà1,2, Francesca Brunini3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32323202      PMCID: PMC7175820          DOI: 10.1007/s40620-020-00737-w

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


× No keyword cloud information.
In the last 6 months, starting from China and the Eastern Countries and spreading to Europe and the United States, a new strand of Coronavirus, SARS-CoV-2, is challenging healthcare systems world-wide [1]. The clinical course of the infection may vary from a more frequent asymptomatic condition to a mild and non-specific respiratory syndrome to, fortunately less frequent, generalized and violent inflammatory response needing ICU assistance, mechanical ventilation and sometime renal replacement therapy [1, 2]. Based on the data so far available, taking into account the possible bias related to different methods of collecting and categorizing data among the various Countries, the lethality index of the SARS-CoV-2 infection would seems not so high. Nevertheless, the fast speed of diffusion with a high rate of patients needing hospitalization and the resulting health system overload, compelled the involved Nations to adopt strict containment strategies with economic consequences that will last for many years in the future. In the absence of any specific therapies or vaccines, the containment strategies are basically oriented to achieve dilution in time of new cases and, as a consequence, to enable the health system to better handle the most demanding ones (Fig. 1) [3].
Fig. 1

Impact of workload over time on the possibility to manage it on the health care system. Areas under the curves are equal

Impact of workload over time on the possibility to manage it on the health care system. Areas under the curves are equal Anyway, the strategies to control the disease spreading may be very complex, due to the lack of precise knowledge about the natural history of the disease and the presence of non-documented asymptomatic or oligo-symptomatic cases, which may spread the infection and probably account for more than 80% of the total infected individuals [4, 5]. As expected, mortality is much higher in the elderly with multiple comorbidities. In this context some populations, such as dialysis patients, may have a very high prevalence and death rate for COVID-19, since they combine older age, malnutrition, cardiovascular disease, diabetes, lung disease and less efficient immune system with the need for dialysis treatment in overcrowded settings where many patients, nurses, physicians and support staff are present at the same time. A number of articles focusing on recommendations to contain the spread of infection in dialysis patients, have been released [2, 6, 7], anyway, very few reports on the real degree of diffusion of the infection and its outcome in this specific population and among people working in dialysis facilities have been published so far. Yiqiong Ma [8], from the Department of Nephrology Renmin Hospital of Wuhan University, reported 37 COVID-19 positive among 230 HD patients and four cases among 33 staff members (16% of the patients and 12% among the personnel respectively). In the 37 COVID -19 positive patients, 6 (16.2%) died. Although CT images of the chest showed the ground glass like changes, symptoms were mild, and none was admitted to ICU. The Authors underline that none of them died because of COVID-19. About 15 days later, after increasing protection measures, the universal screening and the isolation of the infected cases, the risk of infection was under control and no new cases were observed. Cheng Li [9], from the Department of Blood Purification Center, Wuhan No.1 Hospital, Wuhan China, in a preprint report documents a wider experience from the same region where the pandemic started. The report records 66 out of 627 HD patients certainly infected (10.5%), and 24 cases “suspected” (i.e. the diagnosis was made just on clinical ground). The Authors treat the “suspected” cases as if they were real positives, thus, based on this assumption, the infection prevalence rate was 14.3% (90/627). The Authors do not report if the mortality rate between the two subgroups (proven infected and suspected ones) was different, however, putting it all together the mortality rate was 13.3% (12 patients out of 90 with confirmed or suspected infection). Since these two reports come from the same area of China and both the hospitals most likely use the same protocols, putting the two series together, with the limits of that presumption, we obtain a prevalence of Coronavirus infection among dialysis patients of about 16% (137 infected out of 857 HD patients) and a mortality rate of 13.1% (18 dead out of 137 infected HD patients). These data clearly show that the mortality in HD patients is much higher than in the general population, 13% vs 4% respectively (4% is the official mortality in the general COVID-19 population reported in China). Nevertheless, although the infection may be fatal, COVID-19 symptoms in dialysis patients seem to be less aggressive, therefore it was postulated that they may be relatively protected from violent cytokine storm by their impaired immune system [8]. In our opinion the question of whether a patient die for COVID-19 or with COVID-19 is misleading and perhaps it is going to remain unanswered. There is no doubt that in such complex and fragile patients, a violent infection, that mainly targets lungs and heart, already very compromised for many years of dialysis, brings a very high risk of death, even if the infection itself is not the final cause [1, 2, 10, 11]. The data reported by the two reports mentioned above, are very close to those observed in a very preliminary survey in Lombardy (Italy)  (unpublished). In this series about 650/6000 (11%) HD-patients with symptoms resembling those of COVID-19 infection were tested and among them only 301 were positive (5% of the entire population which this preliminary observation refers to). In this subset the mortality was 22.3% (67 dead out of 301 COVID positive patients). With regard to death cause during COVID-19 emergency, other intriguing issues need to be addressed. First of all, the recorded deaths for hyperkalemia [8, 9], in context where dialysis frequency was reduced to minimize infection risk, should raise the question on how many victims of other diseases will be indirectly related to coronavirus epidemic. Second, Cheng Li [9] reports that two patients died despite mechanical ventilation. We don’t know the clinical course and the complications that these two patients had during their stay in the ICU. However, it is important to stress that all dialysis patients have significant diastolic heart disease, thus, even a small increase of Positive End Expiratory Pressure (PEEP) in both cases of NIV with helmet or mechanical ventilation, may significantly decreases left ventricular filling and lead to a low cardiac output. Another important point of the paper of Yiqiong Ma [8] is the focus on infection control strategies. In fact it documents the effectiveness of the measures taken for the infection spreading containment, both for patients and healthcare professionals. This is particularly important in HD patients population because they cannot respect the quarantine, needing dialysis treatment at the hospital, and there is no guarantee that they correctly follow the preventive measures at home. Furthermore dialysis staff members are highly specialized and difficult to replace in case of COVID-19 diffusion. Being symptoms in HD patients often mild and underestimated, as previously stated, and considering that even completely asymptomatic patients can spread the virus [4, 5], it would be appropriate to test dialysis healthcare personnel and patients periodically. The universal screening performed in the paper, beside the upgrade in the protection devices and the isolation measures, proved successful. These measures should be undertaken in all dialysis facilities as soon as possible, even when there are no positive cases. If correctly applied, they reduce the virus transmission between patients, and between healthcare professionals, avoiding the collapse of dialysis activity and preventing the disease from spreading without control even outside the dialysis setting.
  9 in total

1.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

2.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

3.  COVID-19 and the cardiovascular system.

Authors:  Ying-Ying Zheng; Yi-Tong Ma; Jin-Ying Zhang; Xiang Xie
Journal:  Nat Rev Cardiol       Date:  2020-05       Impact factor: 32.419

4.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

5.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).

Authors:  Ruiyun Li; Sen Pei; Bin Chen; Yimeng Song; Tao Zhang; Wan Yang; Jeffrey Shaman
Journal:  Science       Date:  2020-03-16       Impact factor: 47.728

6.  COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?

Authors:  T Alp Ikizler
Journal:  Am J Kidney Dis       Date:  2020-03-23       Impact factor: 8.860

Review 7.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

8.  Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy.

Authors:  Giuseppe Rombolà; Marco Heidempergher; Luciano Pedrini; Marco Farina; Filippo Aucella; Piergiorgio Messa; Giuliano Brunori
Journal:  J Nephrol       Date:  2020-04       Impact factor: 3.902

9.  The Novel Coronavirus 2019 epidemic and kidneys.

Authors:  Saraladevi Naicker; Chih-Wei Yang; Shang-Jyh Hwang; Bi-Cheng Liu; Jiang-Hua Chen; Vivekanand Jha
Journal:  Kidney Int       Date:  2020-03-07       Impact factor: 10.612

  9 in total
  17 in total

1.  Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis.

Authors:  Jacqueline Lee; Jennifer Steel; Maria-Eleni Roumelioti; Sarah Erickson; Larissa Myaskovsky; Jonathan G Yabes; Bruce L Rollman; Steven Weisbord; Mark Unruh; Manisha Jhamb
Journal:  Kidney360       Date:  2020-10-20

2.  Lived Experiences of Patients Receiving Hemodialysis during the COVID-19 Pandemic: A Qualitative Study from the Quebec Renal Network.

Authors:  Marie-Françoise Malo; Aliya Affdal; Dan Blum; Fabian Ballesteros; William Beaubien-Souligny; Marie-Line Caron; Annie-Claire Nadeau-Fredette; Murray Vasilevsky; Norka Rios; Marie-Chantal Fortin; Rita S Suri
Journal:  Kidney360       Date:  2022-04-25

3.  Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry.

Authors:  Aitor Uribarri; Iván J Núñez-Gil; Alvaro Aparisi; Victor M Becerra-Muñoz; Gisela Feltes; Daniela Trabattoni; Inmaculada Fernández-Rozas; María C Viana-Llamas; Martino Pepe; Enrico Cerrato; Thamar Capel-Astrua; Rodolfo Romero; Alex F Castro-Mejía; Ibrahim El-Battrawy; Javier López-País; Fabrizio D'Ascenzo; Oscar Fabregat-Andres; Alfredo Bardají; Sergio Raposeiras-Roubin; Francisco Marín; Antonio Fernández-Ortiz; Carlos Macaya; Vicente Estrada
Journal:  J Nephrol       Date:  2020-06-29       Impact factor: 3.902

4.  When a nephrology ward becomes a COVID-19 ward: the Cremona experience.

Authors:  Fabio Malberti; Paola Pecchini; Gianluca Marchi; Marina Foramitti
Journal:  J Nephrol       Date:  2020-08       Impact factor: 3.902

Review 5.  Novel coronavirus disease in patients with end-stage kidney disease.

Authors:  Noriaki Shimada; Hiroaki Shimada; Yoshiaki Itaya; Yasuhiko Tomino
Journal:  Ther Apher Dial       Date:  2020-10-27       Impact factor: 2.195

6.  Genetic epidemiology of SARS-CoV-2 transmission in renal dialysis units - A high risk community-hospital interface.

Authors:  Kathy K Li; Y Mun Woo; Oliver Stirrup; Joseph Hughes; Antonia Ho; Ana Da Silva Filipe; Natasha Johnson; Katherine Smollett; Daniel Mair; Stephen Carmichael; Lily Tong; Jenna Nichols; Elihu Aranday-Cortes; Kirstyn Brunker; Yasmin A Parr; Kyriaki Nomikou; Sarah E McDonald; Marc Niebel; Patawee Asamaphan; Vattipally B Sreenu; David L Robertson; Aislynn Taggart; Natasha Jesudason; Rajiv Shah; James Shepherd; Josh Singer; Alison H M Taylor; Zoe Cousland; Jonathan Price; Jennifer S Lees; Timothy P W Jones; Carlos Varon Lopez; Alasdair MacLean; Igor Starinskij; Rory Gunson; Scott T W Morris; Peter C Thomson; Colin C Geddes; Jamie P Traynor; Judith Breuer; Emma C Thomson; Patrick B Mark
Journal:  J Infect       Date:  2021-04-22       Impact factor: 6.072

7.  Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology.

Authors:  Giuseppe Quintaliani; Gianpaolo Reboldi; Anteo Di Napoli; Maurizio Nordio; Aurelio Limido; Filippo Aucella; Piergiorgio Messa; Giuliano Brunori
Journal:  J Nephrol       Date:  2020-07-03       Impact factor: 3.902

8.  Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis.

Authors:  Jonathan Feld; Douglas Tremblay; Santiago Thibaud; Alaina Kessler; Leonard Naymagon
Journal:  Int J Lab Hematol       Date:  2020-08-13       Impact factor: 2.877

9.  COVID-19 and maintenance hemodialysis: a systematic scoping review of practice guidelines.

Authors:  Hossein Akbarialiabad; Shahin Kavousi; Aria Ghahramani; Bahar Bastani; Nasrollah Ghahramani
Journal:  BMC Nephrol       Date:  2020-11-10       Impact factor: 2.388

10.  The reliability and success of peritoneal dialysis during the COVID-19 pandemic.

Authors:  Hasan H Yeter; Ebru Gok Oguz; Omer F Akcay; Refika Karaer; Emre Yasar; Murat Duranay; Mehmet D Ayli; Galip Guz
Journal:  Semin Dial       Date:  2020-11-19       Impact factor: 2.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.